A selective inhibitor of TXA synthase
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Ozagrel

Item No. 70515

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2E-propenoic acid
CAS Number
82571-53-7
Synonyms
  • OKY-046
Molecular Formula
C13H12N2O2
Formula Weight
228.3
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 1 mg/mlDMSO: 5 mg/mlDMSO:PBS (pH 7.2) (1:1): 1 mg/ml
λmax
275 nm
SMILES
OC(/C=C/C1=CC=C(CN2C=CN=C2)C=C1)=O
InChi Code
InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+
InChi Key
SHZKQBHERIJWAO-AATRIKPKSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $38

    Add

    10 mg

    $71

    Add

    50 mg

    $291

    Add

    100 mg

    $505

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Ozagrel is a 1-alkyl imidazole derivative that acts as a selective inhibitor of TXAS with an IC50 of 11 nM. The beneficial effects of TXAS inhibition by ozagrel include improved motor coordination after experimental stroke,1 and antihypertensive effects in spontaneously hypertensive rats.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ichikawa, K., Tazawa, S., Hamano, S., et al. Effect of ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models. Pharmacology 59, 257-265 (1999).

    2. Press, J.B., Wright, W.B., Jr., Chan, P.S., et al. Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-Imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones as unique antihypertensive agents. J. Med. Chem. 29(5), 816-819 (1986).

    Product Citations

    Johnsson, A.K., Choi, J.H., Rönnberg, E., et al. Selective inhibition of prostaglandin D2 biosynthesis in human mast cells to overcome need for multiple receptor antagonists: Biochemical consequences. Clin. Exp. Allergy 51(4), 594-603 (2021).